ABUS - Arbutus Biopharma Corporation
| Previous Close | 6.40 |
| Open | 6.35 |
| Bid | 5.65 x 1000 |
| Ask | 6.25 x 1800 |
| Day's Range | 6.05 - 6.45 |
| 52 Week Range | 3.20 - 8.25 |
| Volume | 126,636 |
| Avg. Volume | 165,222 |
| Market Cap | 336.525M |
| Beta | 2.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.56 |
| Earnings Date | May 2, 2018 - May 7, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.32 |
- ACCESSWIRE•13 days ago
Blog Exposure - Spectrum Pharma Inked Licensing Agreement with The University of Texas MD Anderson Cancer Center on Certain Methods of Use of Poziotinib
LONDON, UK / ACCESSWIRE / May 07, 2018 / If you want access to our free research report on Spectrum Pharma, Inc. (NASDAQ: SPPI), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SPPI as the Company's latest news hit the wire. On May 03, 2018, the Company announced that it has inked an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center for intellectual property related to exon 20 and certain methods of use of poziotinib. Active-Investors.com is currently working on the research report for Arbutus Biopharma Corporation (NASDAQ: ABUS), which also belongs to the Healthcare sector as the Company Spectrum Pharma.
- Associated Press•17 days ago
Arbutus: 1Q Earnings Snapshot
The Burnaby, British Columbia-based company said it had a loss of 36 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- Forbes•17 days ago
Merck Teams With Moderna To Take On One Of The Toughest Targets In Cancer
Pipettes are seen at the Moderna Therapeutics Inc. lab in Cambridge, Massachusetts, U.S., on Tuesday, Nov. 14, 2017. In a quest to augment its blockbuster cancer drug Keytruda, Merck is tapping Moderna, a controversial Cambridge, Mass.-based biotech, to develop an anti-cancer vaccine that targets one of the toughest targets in drug development. This will be different: an off-the-shelf vaccine that would be given to patients whose tumors test positive for a gene called KRAS.
- GlobeNewswire•17 days ago
Arbutus Announces Corporate Update and First Quarter 2018 Financial Results
Two Novel HBV Candidates Planned to Enter Clinical Development in 2018 GalNAc Conjugated RNAi Agent Nominated to Enter IND-Enabling Studies Strategic Partnership with Roivant to Launch Genevant, an RNA ...
- GlobeNewswire•20 days ago
Arbutus Announces Conference Call to Provide a Corporate Update and First Quarter 2018 Financial Results
VANCOUVER, British Columbia and WARMINSTER, Pa., April 30, 2018-- Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced that it will hold a ...
- GlobeNewswire•last month
Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018
Capsid inhibitor with HBV RNA Destabilizer Demonstrate Complementary Efficacy Results Subcutaneous RNAi Agent Demonstrates Durable HBsAg Reduction Following a Single Dose. VANCOUVER, British Columbia and ...
- GlobeNewswire•last month
Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases
Genevant aims to advance 5-10 product candidates into the clinic by 2020 across RNAi, mRNA, and gene editing modalities using Arbutus’ LNP and ligand conjugate platforms Genevant will be led by Executive ...
- GlobeNewswire•last month
New Research: Key Drivers of Growth for Talend S.A, Chipmos Technologies, POSCO, Horizon Pharma Public, BioSpecifics Technologies, and Arbutus Biopharma — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, April 11, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•2 months ago
Arbutus to Present HBV Data at 2018 EASL Liver Meeting
VANCOUVER, British Columbia and WARMINSTER, Pa., March 28, 2018-- Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced presentation of data ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ABUS earnings conference call or presentation 15-May-07 4:00pm GMT
Q1 2007 Inex Pharmaceuticals Corporation Earnings Conference Call
- Benzinga•2 months ago
Wedbush Projects Limited Upside For Arbutus Shares This Year, Moves To Sidelines
While Wedbush predicts Arbutus Biopharma Corp (NASDAQ: ABUS ) shares will appreciate over the next six-to-12 months amid clinical data readouts, the sell-side firm stepped to the sidelines following the ...
- GlobeNewswire•2 months ago
Report: Developing Opportunities within Capital Product Partners, Adient, Arbutus Biopharma, GW Pharmaceuticals, Customers, and Laureate Education — Future Expectations, Projections Moving into 2018
NEW YORK, March 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ABUS earnings conference call or presentation 14-Mar-18 8:30pm GMT
Q4 2017 Arbutus Biopharma Corp Earnings Call
- GlobeNewswire•2 months ago
Arbutus Announces Corporate Update and Year-End 2017 Financial Results
ARB-1467 Phase II Combination Study Beginning in 1 Q18 Two New Drug Candidates Planned to Enter Clinical Development in 2 H18 Over $200 M in Cash Available to Fund Development of HBV Assets Company to ...
- Simply Wall St.•2 months ago
Arbutus Biopharma Corporation (NASDAQ:ABUS) Is Expected To Breakeven
Arbutus Biopharma Corporation’s (NASDAQ:ABUS): Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in CanadaRead More...
- GlobeNewswire•2 months ago
Arbutus Announces Conference Call to Provide a Corporate Update and Fourth Quarter 2017 Year-End Financial Results
VANCOUVER, British Columbia and WARMINSTER, Pa., March 12, 2018-- Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced that it will hold a ...
- GlobeNewswire•3 months ago
Arbutus Settles Litigation, Terminating Acuitas’ Rights to LNP Technology
Acuitas has No Further Rights to Use or Sublicense Arbutus LNP Technology Arbutus Consolidates LNP Patent Estate Enabling RNAi, mRNA, and Gene-editing Therapeutics. VANCOUVER, B.C. and WARMINSTER, Pa., ...
- Simply Wall St.•3 months ago
Should Arbutus Biopharma Corporation’s (NASDAQ:ABUS) Recent Earnings Decline Worry You?
Measuring Arbutus Biopharma Corporation’s (NASDAQ:ABUS) track record of past performance is an insightful exercise for investors. It enables us to reflect on whether the company has met or exceed expectations,Read More...
- Capital Cube•6 months ago
Arbutus Biopharma Corp. breached its 50 day moving average in a Bullish Manner : ABUS-US : November 28, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Arbutus Biopharma Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
